For HER2-positive disease, chemotherapy and HER2-targeted therapy.
Ideally, the entire treatment regimen is administered before surgery.
For postmenopausal women with hormone receptorâ€“positive breast cancer, chemotherapy is an option.
For those who cannot be given chemotherapy, preoperative endocrine therapy may be an option.
For premenopausal women with hormone-responsive cancer, the use of preoperative endocrine therapy is under investigation.
Regular clinical assessment of response to therapy is necessary after beginning preoperative therapy.
Repeat radiographic assessment is also required if breast conservation is the surgical goal.